StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Symbicort (budesonide/formoterol) by Quarter

Symbicort (budesonide/formoterol) — US product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Symbicort (budesonide/formoterol): $254M in Q2 2026, down 20.4% from a year earlier.

Latest, Q2 2026
254
Period ended Jun 30, 2026
Change on a year earlier
-20.4%
319 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Symbicort | 671 | | ( 6 ) | | ( 8 ) | | 254 | | ( 20 ) | | 191 | | 14 | | 10 | | 145 | | 6 | | 2 | | 81 | | ( 12 ) | | ( 14 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSymbicort (budesonide/formoterol) — US product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026254-20.4%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026290+3.9%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025289-3.3%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025305+5.5%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025319+6.7%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025279-6.7%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024299+118.2%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024289+85.3%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024299+49.5%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024299+28.3%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023137-46.3%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023156-34.2%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023200-9.9%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023233-10.0%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022255-2.7%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022237-13.5%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up symbicort (budesonide/formoterol)

Cite this data

StockData. (2026). AstraZeneca Symbicort (budesonide/formoterol) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-symbicort-us

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?